A Long Term Follow-up Study of TScan TCR-T Products
← catalyst calendarNCT06976736 · readout ≤ 5,156 d
Sponsored by TScan Therapeutics, Inc. (industry) · TCRX — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
1,000estimated
Sites
2
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-09-09 | estimated | When the study began enrolling |
| Primary completion | Sep 2040 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Sep 2040 | estimated | The whole study's end, after follow-up |
| First posted | 2025-05-16 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-09-10 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- AML
- ALL
- MDS
Intervention
- Other: Observational
Primary outcome
what the primary-completion date above is the date OFIncidence of Treatment-Emergent Adverse Events (Safety and Tolerability)
measured 15 years post TCR-T administration
Permalink · TCRX's whole pipeline · Catalyst calendar · Every registered study · What changed